Cargando…
Long‐term outcomes in corticosteroid‐refractory Graves' orbitopathy treated with tocilizumab
BACKGROUND: Up to 20% of patients with moderate to severe Graves' orbitopathy (GO) do not respond to high‐dose glucocorticoids (GC). A few studies, including a randomized trial, have demonstrated the efficacy of interleukin‐6 (IL‐6) blockade with tocilizumab (TCZ) in GC‐refractory GO. However,...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545295/ https://www.ncbi.nlm.nih.gov/pubmed/34908176 http://dx.doi.org/10.1111/cen.14655 |